

# Ensuring Medication for Opioid Use Disorder (MOUD) Treatment through the Care Continuum Webinar Series



*More than 1 million Medicare beneficiaries had a diagnosis of opioid use disorder in 2020.<sup>1</sup>*

*However, fewer than 1 in 5 Medicare beneficiaries with an opioid use disorder (OUD) diagnosis received medication to treat this condition. In addition, the number of patients who stay in treatment after hospital discharge decrease drastically during the transition of care.<sup>2</sup>*

**This webinar series is a collaboration of all of the Quality Innovation Network-Quality Improvement Organizations and will provide strategies, interventions, and targeted solutions to ensure access to MOUD treatment and facilitate the continuity of care through the continuum.**

**Please join us to hear from national experts during this monthly webinar series occurring on Friday of the month from September 2023 through June 2024 at 12 noon ET, 11 a.m. CT, 10 a.m. MT, 9 a.m. PT**

**Register for this no-cost series at: <https://bit.ly/MOUDthroughCareContinuumSeries>**

**Session 1—September 15, 2023:** Role of the Emergency Department (ED) Physician in the Treatment of Patients with OUD

*Basics & science of addiction and screening & initiating MOUD.*

**Session 2—October 13, 2023:** Role of the Pharmacist in the Treatment of Patients with OUD

*Medication processes, addressing opioid adverse drug events (ADEs), and risk assessment for opioid prescribing.*

**Sessions 3 (Part 1: Presentation) and 4 (Part 2: Panel Discussion)—November 17, 2023, and**

**January 12, 2024:** Seamlessly Transitioning Patients on MOUD to Nursing Homes

*Discharge planning, medication reconciliation, and readmission prevention.*

**Sessions 5 (Part 1: Presentation) and 6 (Part 2: Panel Discussion)—February 9, 2024, and**

**March 8, 2024:** Management of Patients on MOUD During the Nursing Home Stay

*Admissions assessment & treatment, addressing stigma, and naloxone training.*

**Sessions 7 (Part 1: Presentation) and 8 (Part 2: Panel Discussion)—April 12, 2024, and May 10,**

**2024:** Sustaining Recovery for Patients on MOUD

*Alternatives to Opioids (ALTO), peer support, narcotics anonymous meetings, counseling, and use of technologies.*

**Session 9—June 7, 2024:** Management of Patients on MOUD: Key Takeaways and Series Wrap Up

A general certificate of attendance will be provided for continuing education/contact hours. Attendees are responsible for determining if this program meets the criteria for licensure or recertification for their discipline.

**For questions about the series, contact Shirley Sullivan ([sullivan@qualityinsights.org](mailto:sullivan@qualityinsights.org)).**

<sup>1</sup> Health and Human Services: Office of Inspector General. Combating the Opioid Epidemic OIG Report. May 18, 2023. Accessed on: August 2, 2023. Available at: <https://oig.hhs.gov/reports-and-publications/featured-topics/opioids/>

<sup>2</sup> Klimas J, Hamilton M, et al. Retention in Opioid Agonist Treatment: A Rapid Review and Meta-Analysis Comparing Observational Studies and Randomized Controlled Trials. August 6, 2021. Available at: <https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-021-01764-9>